1.Ox-LDL suppresses PMA-induced MMP-9 expression and activity through CD36-mediated activation of PPAR-gamma.
Kyoung Jin LEE ; Hyun A KIM ; Pyeung Hyeun KIM ; Han soo LEE ; Kyung Ran MA ; Jeong Hyun PARK ; Dae Joong KIM ; Jang Hee HAHN
Experimental & Molecular Medicine 2004;36(6):534-544
During chronic inflammatory response, mono- cytes/macrophages produce 92-kDa matrix metalloproteinase-9 (MMP-9), which may contribute to their extravasation, migration and tissue remodeling. Activation of peroxisome proliferator- activated factor receptor-gamma (PPAR-gamma) has been shown to inhibit MMP-9 activity. To evaluate whether ox-LDL, a PPAR-gamma activator, inhibits PMA-induced MMP-9 expression and activity, and if so, whether CD36 and PPAR-gamma are involved in this process, we investigated the effect of ox-LDL on MMP-9 expression and activity in PMA-activated human monocytic cell line U937. PMA-induced MMP-9 expression and activity were suppressed by the treatment with ox-LDL (50 micrigram/ml) or PPAR-gamma activators such as troglitazone (5 micrometer), ciglitazone (5 micrometer), and 15d- PGJ2 (1 micrometer) for 24 h. This ox-LDL or PPAR-gamma activator-mediated inhibition of micrometer P-9 activity was diminished by the pre-treatment of cells with a blocking antibody to CD36, or PGF2a (0.3 micrometer), which is a PPAR-gamma inhibitor, as well as overexpression of a dominant-negative form of CD36. Taken together, these results suggest that ox-LDL suppresses PMA-induced MMP-9 expression and activity through CD36-mediated activation of PPAR-gamma.
Antibodies, Blocking/pharmacology
;
Antigens, CD36/immunology/*physiology
;
Cells, Cultured
;
Chromans/pharmacology
;
Gelatinase B/antagonists & inhibitors/genetics/*metabolism
;
Humans
;
Lipoproteins, LDL/pharmacology/*physiology
;
Monocytes/drug effects/*enzymology/metabolism
;
NF-kappa B/antagonists & inhibitors
;
PPAR gamma/*metabolism
;
Prostaglandin D2/*analogs & derivatives/pharmacology
;
RNA, Messenger/analysis/metabolism
;
Research Support, Non-U.S. Gov't
;
Tetradecanoylphorbol Acetate/antagonists & inhibitors/pharmacology
;
Thiazolidinediones/pharmacology
;
Transcription, Genetic/drug effects
2.Tetraspanin CD9 induces MMP-2 expression by activating p38 MAPK, JNK and c-Jun pathways in human melanoma cells.
In Kee HONG ; Young Myeong KIM ; Doo Il JEOUNG ; Keun Cheol KIM ; Hansoo LEE
Experimental & Molecular Medicine 2005;37(3):230-239
Expression of matrix metalloproteinase-2 and -9 (MMP-2 and MMP-9), which correlates with tumor invasion and metastasis, has been known to be regulated by several intracellular signaling pathways. Since the CD9 membrane protein has been implicated in signal transduction and malignant progression of cancer cells, we examined the functional involvement of CD9 in the regulation of MMP-2 and MMP-9 expression by using stable CD9 transfectant clones of MelJuso human melanoma cells. The CD9 cDNA-transfected cells with elevated CD9 expression displayed increased MMP-2 and decreased MMP-9 expression when compared with the mock transfectant cells. Among several signal pathway inhibitors tested, SB203580 and SP600125, which inhibit p38 MAPK and JNK respectively, completely blocked the CD9-stimulated MMP-2 expression. Phosphorylation levels of p38 MAPK and c-Jun in MelJuso cells were also significantly increased by CD9 transfection. In addition, the down-regulation of p38 MAPK and JNK by siRNA transfection resulted in a decrease in MMP-2 expression by MelJuso cells. Promoter analysis and gel shift assay showed that the CD9-induced MMP-2 expression is mediated by a functional AP-1 site through interactions with AP-1 transcription factors including c-Jun. These results suggest that CD9 induces MMP-2 expression by activating c- Jun through p38 MAPK and JNK signaling pathways in human melanoma cells.
Antigens, CD/*metabolism
;
Electrophoretic Mobility Shift Assay
;
Enzyme Activation
;
Gelatinase A/genetics/*metabolism
;
Gelatinase B/metabolism
;
Humans
;
JNK Mitogen-Activated Protein Kinases/antagonists & inhibitors/genetics/*metabolism
;
Melanoma/*metabolism/pathology
;
Membrane Glycoproteins/*metabolism
;
Promoter Regions (Genetics)
;
Proto-Oncogene Proteins c-jun/*metabolism
;
RNA, Small Interfering/pharmacology
;
Research Support, Non-U.S. Gov't
;
*Signal Transduction
;
Skin Neoplasms/metabolism/pathology
;
Transcription Factor AP-1/metabolism
;
Transfection
;
p38 Mitogen-Activated Protein Kinases/antagonists & inhibitors/genetics/*metabolism